The therapeutic potential of duloxetine in prostate cancer-related fatigue

Abstract

Cancer-related fatigue (CRF) is a common polysymptomatic syndrome with no standard therapy. The authors present the case of a prostate cancer patient in whom, during hormone therapy, disabling CRF and urinary incontinence occurred. CRF was assessed according to the brief fatigue inventory (BFI). The patient received duloxetine, 60 mg daily, due to its impact on both CRF and incontinence. After 2 months, the BFI score decreased (from 9 to 2) and urinary incontinence resolved. After duloxetine discontinuation, the patient maintained a low BFI score. The authors conclude that, as a serotonin-noradrenaline reuptake inhibitor, duloxetine could be active on prostate CRF, especially with associated urinary symptoms. Therefore, a pilot placebo-controlled trial with duloxetine to treat prostate CRF may be worthwhile.

Keywords

Duloxetine / fatigue / prostate cancer

References

[1] National Comprehensive Cancer Network Practice Guidelines. Cancer-related Fatigue Guidelines; 2014. Available from: http://www.nccn.org. [Last accessed on 2014 Oct 18].

[2] Whitehead L.The measurement of fatigue in chronic illness: a systematic review of unidimensional and multidimensional fatigue measures..J Pain Symptom Manage2009;37:107-28

[3] Meneses-Echávez JF,Ramírez-Vélez R.Effects of supervised multimodal exercise interventions on cancer-related fatigue: systematic review and meta-analysis of randomized controlled trials..Biomed Res Int2015;2015:328636 PMCID:PMC4488083

[4] Sonn GA,Presti JC.Differing perceptions of quality of life in patients with prostate cancer and their doctors..J Urol2009;2:2296-302

[5] Saylor PJ.Metabolic complications of androgen deprivation therapy for prostate cancer..J Urol2009;181:1998-2006 PMCID:PMC2900631

[6] Stone P,Huddart R,Richards M.Fatigue in patients with prostate cancer receiving hormone therapy..Eur J Cancer2000;36:1134-41

[7] Kyrdalen AE,Hernes E,Fossa SD.Fatigue in prostate cancer survivors treated with definitive radiotherapy and LHRH analogs..Prostate2010;70:1480-9

[8] Capuron L.Immune system to brain signalling: neuropsychopharmacological implications..Pharmacol Ther2011;130:226-38 PMCID:PMC3072299

[9] de la Cruz M,Parsons HA.Placebo and nocebo effects in randomized double-blind clinical trials of agents for the therapy for fatigue in patients with advanced cancer..Cancer2010;116:766-74 PMCID:PMC2815077

[10] Minton O,Sharpe M,Stone P.A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue..J Natl Cancer Inst2008;20:1155-66

[11] Nelson CJ,Roth AJ.The association between erectile dysfunction and depressive symptoms in men treated for prostate cancer..J Sex Med2011;8:560-6

[12] Carroll JK,Mustian KM,Morrow GR.Pharmacologic treatment of cancer-related fatigue..Oncologist2007;12:43-51

[13] Morrow GR,Roscoe JA,Andrews PL,Hynes HE,Kirshner JJ,University of Rochester Cancer Center Community Clinical Oncology Program.Differential effects of paroxetine on fatigue and depression: a randomized, double-blind trial from the University of Rochester Cancer Center Community Clinical Oncology Program..J Clin Oncol2003;21:4635-41

[14] Bellato E,Castoldi F,Mattei L,Blonna D.Fibromyalgia syndrome: etiology, pathogenesis, diagnosis and treatment..Pain Res Treat2012;2012:426130

[15] Knadler MP,Chappell J.Duloxetine: clinical pharmacokinetics and drug interactions..Clin Pharmacokinet2011;50:281-94

[16] Mease PJ.Further strategies for treating fibromyalgia: the role of serotonin and norepinephrine reuptake inhibitors..Am J Med2009;122:S44-55

[17] Ahlberg K,Gaston-Johansson F.Assessment and management of cancer-related fatigue in adults..Lancet2003;362:640-50

[18] Mottet N, Bastian PJ, Bellmunt J, van den Bergh RC, Bolla M, van Casteren NJ, Cornford P, Joniau S, Mason MD, Matveev V, van der Kwast TH, van der Poel H, Rouvière O, Wiegel T. Guidelines on Prostate Cancer, European Association of Urology; 2014. Available from: http://uroweb.org/guideline/prostate-cancer/ [Last accessed on 2015 Aug 14].

[19] Roscoe JA,Hickok JT,Griggs JJ,Bushunow P,Smith B.Effect of paroxetine hydrochloride (Paxil) on fatigue and depression in breast cancer patients receiving chemotherapy..Breast Cancer Res Treat2005;89:243-9

[20] de Saint Hilaire Z,Rouch C,Nicolaidis S.Variations in extracellular monoamines in the prefrontal cortex and medial hypothalamus after modafinil administration: a microdialysis study in rats..Neuroreport2001;12:3533-7

[21] Kuczenski R.Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine..J Neurochem1997;68:2032-7

[22] Gronier B.In vivo electrophysiological effects of methylphenidate in the prefrontal cortex: involvement of dopamine D1 and alpha 2 adrenergic receptors..Eur Neuropsychopharmacol2011;21:192-204